Innovations in Biopharma 2025

Ben is the Chief Technology Officer and Head of Platform at PhoreMost Ltd, a pre-clinical drug discovery company based in Cambridge, UK. He is a geneticist & biotechnologist and has pioneered the use of computationally engineered mini-proteins to enable new medicine development, including bivalent and monovalent degrader-based drugs. Ben has research expertise in proteostasis, functional genomics and chemical genetic screening and in 2014 founded the UKs first CRISPR-based functional genomics screening platform. He is the inventor of the GlueSEEKER platform at PhoreMost and has authored over 30 peer reviewed studies and patents working at the intersection of biology, drug discovery and data science. As a serial biotech platform builder, Ben has a particular proclivity for collaboration and for engineering business alliances across the life sciences sector.

Dr. Craig Eagle currently serves as Guardant Health’s chief medical officer. Prior to joining Guardant Health, Dr. Eagle served as Vice President of Medical Affairs Oncology for Genentech, where he oversaw the medical programs across the oncology portfolio and developed innovative cancer trials and strategies in personalized health care. Prior to Genentech, Dr. Eagle has held several positions in the U.S. and internationally over his 19-year career at Pfizer including global head of the Oncology Medical and Outcomes Group. In this role, he oversaw the worldwide medical programs and development of numerous commercially successful drugs. Dr. Eagle currently serves on the Board of Directors for Generex Biotechnology and NuGenerex Immuno-Oncology. Dr. Eagle attended medical school at the University of New South Wales in Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. Dr. Eagle completed his specialist training in hemato-oncology and laboratory hematology at Royal Prince Alfred Hospital in Sydney and was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA).

Dr. Raviv Pryluk is co-founder and CEO of PhaseV, a pioneer in causal machine learning (ML) for clinical trial analysis and optimization. Prior to his tenure at PhaseV, Dr. Pryluk held integral roles in operations and data analytics at Immunai, a biotechnology company specializing in the mapping and reprogramming of immunology. Before that Dr. Pryluk was a technological leader in the advanced technological defense industry for over a decade. He holds a BSc and MSc in aerospace, aeronautical, and astronautical engineering from Technion (Cum Laude) and a Ph.D. in neurobiology and neurosciences from the Weizmann Institute of Science (Summa cum laude).

Professor Mallory Factor KCNG is the Founder, President and CEO of IntraBio Inc. A serial entrepreneur, Professor Factor has successfully launched, developed and/or invested in numerous early-stage companies over his 30-year career, including two medical devices startups which resulted in an IPO and a successful trade sale, respectively. Professor Factor has had an extensive career in both the public and private sectors, including as the Founder and President of Mallory Factor Inc., which advises and invests in private and public biotechnology, technology, and manufacturing companies. He has served as a Member of the Board of Governors of the New York State Banking Department, the Chairman of The New York Public Asset Fund, and a Member (Presidential Appointee) of the Federal Home Loan Bank, Savings and Loan Council, and has testified extensively before Congress as an expert witness. He is a Life Member of the Council on Foreign Relations. Professor Factor received his BA in Biochemistry from Wesleyan University and studied in the Joint Business and Law Program at Columbia University. Professor Factor is currently a Senior Visiting Fellow at the Department of Pharmacology at the University of Oxford, and has retired as the John C. West Professor at The Citadel in Charleston, South Carolina. Professor Factor is a celebrated author of two New York Times Best Selling books, has published dozens of articles, and is a frequent contributor to publications and media including The Wall Street Journal, Forbes Magazine, Sky News, FOXNews and the BBC.

Dr. Ofer Sharon is a physician and entrepreneur with over two decades of experience in clinical research, pharmaceuticals, and biotechnology. Prior to joining OncoHost, Sharon held senior positions in global pharmaceutical companies, including AstraZeneca and MSD (Merck), and was part of the development and clinical launch team for Keytruda. In addition, Sharon has been involved in the establishment of several healthcare companies focused on bioinformatics and machine learning (ML) platforms for clinical deterioration detection and early intervention.

Shalabh Gupta, MD, is the founder of Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategy role at Genentech, Inc.; equity researcher covering US pharmaceutical companies at UBS Investment Bank; and as an equity researcher covering biotechnology companies at Rodman & Renshaw (currently HC Wainwright). Dr. Gupta previously served as a medical advisor to Synageva BioPharma Corporation and as an advisor to New York University (NYU) Langone Medical Center’s Office of Technology Transfer. Dr. Gupta is also the founder and Chief Executive Officer of Globavir, which had licensed diagnostic technology from Stanford university, which was then partnered with global commercial diagnostic companies. Dr. Gupta is an advisor to the UCSF Innovation Center, a role he has held since 2020. Since 2012, and has also been an advisor to SPARK, Stanford University School of Medicine. Dr. Gupta previously served on the board of directors for the Beall Center for Innovation and Entrepreneurship at the University of California Irvine, Paul Merage School of Business. Before his roles in business and finance, Dr. Gupta was an attending physician at NYU Medical Center and a clinical faculty member at the NYU School of Medicine. Dr. Gupta was a board-certified physician, and he currently holds a license from the California State Medical Board. Dr. Gupta completed his internship in Internal Medicine, medical residency in Physical Medicine and Rehabilitation, and research fellowship in Cardiopulmonary Rehabilitation at NYU School of Medicine. Dr. Gupta received his MPA in Health Care Finance and Management from NYU’s Robert F. Wagner Graduate School of Public Service and his MD from Jawaharlal Institute of Postgraduate Medical Education & Research, India.